Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > beenthere and prophetoffacts
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(314)
•••
Comment by beenthereon Dec 02, 2021 4:37pm
105 Views
Post# 34192132

RE:RE:RE:RE:RE:RE:RE:RE:beenthere and prophetoffacts

RE:RE:RE:RE:RE:RE:RE:RE:beenthere and prophetoffactsMike, feel better now?

Got some of that frustration out?

You do realize that your last 3 posts have had nothing to do with BTI!

Say what you like. Doesn't help BTI and I couldn't care less about your little rants!
(actually I find it funny that someone would devote so much time to something that he can not change)

But the one thing that you, chrispi, JD, and anyone else for that matter
can not deny..... the performance of this stock.

...what finished me off ...part time ceo!!

HOW IN HELL CAN THIS COMPANY BE TAKEN SERIOUSLY WITH A part time CEO!!
Think about it!  If you were looking at BTI as an investment what would you do?
I know what I would be doing. I would move to my next possible investment.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities